L.E.K.’s Take on China Medtech: Optimistic Macro View, Short-Term Hit Hard Stephen Sunderland Read more
Related Practice MedTech Despite the COVID-19 lockdown, Stephen Sunderland foresees limited disruption 07102020100744
Case Study Life Sciences & Pharma Value Story and Cross-Stakeholder Action Plan for Oncology Reimbursement May 8, 2024 A big pharma company wanted to enable change in payer attitudes to increase the acceptance of patient-reported outcomes (PROs) and of endpoints beyond…
Case Study Biotech and Pharmaceuticals Pricing Strategy for a Recently Commercialized Rheumatoid Arthritis Drug April 30, 2024 A biopharma company with a recently launched rheumatoid arthritis drug asked L.E.K. Consulting to define the optimal price strategies for the 12-18 months…
Executive Insights Mergers & Acquisitions Keys to Unlocking Merger Value — Revenue Synergies December 18, 2023
Published Articles Life Sciences & Pharma Shifting Geographic Priorities for Healthcare Companies Operating in Asia (Subscription… October 11, 2023